サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1738367

次世代バイオ治療薬市場- 世界の産業規模、シェア、動向、機会、予測、治療領域別、技術別、地域別、競合別、2020-2030年

Next Generation Biotherapeutics Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Therapeutic Area, By Technology, By Region & Competition, 2020-2030F

出版日
ページ情報
英文 185 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.76円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

次世代バイオ治療薬市場- 世界の産業規模、シェア、動向、機会、予測、治療領域別、技術別、地域別、競合別、2020-2030年
出版日: 2025年05月30日
発行: TechSci Research
ページ情報: 英文 185 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

次世代バイオ治療薬（NGBT）の世界市場は、2024年に54億2,000万米ドルと評価され、2030年には107億5,000万米ドルに達し、CAGR 12.05％で成長すると予測されています。

NGBTは、遺伝子治療、細胞治療、RNA干渉、モノクローナル抗体などの先端技術を活用し、正確で個別化された治療を提供するバイオ医薬品の革新的飛躍を意味します。これらの治療法は、特定の疾患メカニズムを標的とするように設計され、副作用を最小限に抑えながら治療効果を向上させる。その応用範囲は多岐にわたり、従来の治療法に反応しない患者に新たな希望をもたらしています。オーダーメイドのデータ主導型ヘルスケアソリューションへの需要が高まる中、NGBTは世界のヘルスケアシステムで急速に普及しています。身体の自然なメカニズムを活性化し、次世代の分子戦略を活用することで、これらのバイオ治療薬は医療治療のパラダイムを再構築しています。継続的な研究開発のブレークスルーにより、NGBTは複雑で以前は治療不可能だった疾患の治療の可能性を進め、より良い臨床結果を提供し、患者ケアの標準を再定義しています。

市場概要
予測期間 2026-2030
市場規模：2024年 54億2,000万米ドル
市場規模：2030年 107億5,000万米ドル
CAGR：2025年～2030年 12.05%
急成長セグメント オンコロジー
最大市場 北米

市場促進要因

がん罹患率の増加

主な市場動向

高齢化人口の増加

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 次世代バイオ治療薬市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 治療領域別（腫瘍学、自己免疫疾患/炎症性疾患）
    • 技術別（抗体薬物複合体、二重特異性抗体、抗体フラグメント、抗体様タンパク質、その他）
    • 地域別
    • 企業別（2024）
  • 市場マップ

第6章 北米の次世代バイオ治療薬市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • カナダ
    • メキシコ

第7章 欧州の次世代バイオ治療薬市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン

第8章 アジア太平洋地域の次世代バイオ治療薬市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋地域：国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第9章 南米の次世代バイオ治療薬市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの次世代バイオ治療薬市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 最近の動向
  • 製品上市
  • 合併と買収

第13章 世界の次世代バイオ治療薬市場：SWOT分析

第14章 競合情勢

  • Xencor, Inc.
  • Regenxbio & Neurimmune AG
  • Takeda Pharmaceutical Company Limited
  • Pfizer, Inc.
  • AstraZeneca Plc.
  • F. Hoffmann-La Roche Ltd.
  • Kyowa Kirin Co., Ltd
  • Seattle Genetics, Inc
  • ImmunoGen, Inc
  • Ono Pharmaceuticals Co, Ltd

第15章 戦略的提言

第16章 調査会社について・免責事項

目次
Product Code: 8069

The Global Next Generation Biotherapeutics (NGBT) Market was valued at USD 5.42 billion in 2024 and is projected to reach USD 10.75 billion by 2030, growing at a CAGR of 12.05%. NGBTs signify a transformative leap in biopharmaceutical innovation, utilizing advanced technologies such as gene therapy, cell therapy, RNA interference, and monoclonal antibodies to deliver precise and personalized treatment. These therapies are engineered to target specific disease mechanisms, improving treatment effectiveness while minimizing adverse effects. Their application spans a wide range of conditions, offering new hope for patients unresponsive to conventional therapies. As the demand for tailored, data-driven healthcare solutions grows, NGBTs are rapidly gaining traction across global healthcare systems. By activating the body's natural mechanisms and harnessing next-gen molecular strategies, these biotherapeutics are reshaping medical treatment paradigms. With continuous R&D breakthroughs, NGBTs are advancing the possibilities of treating complex and previously untreatable diseases, offering better clinical outcomes and redefining standards in patient care.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 5.42 Billion
Market Size 2030USD 10.75 Billion
CAGR 2025-203012.05%
Fastest Growing SegmentOncology
Largest MarketNorth America

Key Market Drivers

Increasing Incidence of Cancer

The escalating global cancer burden is a major factor propelling the demand for Next Generation Biotherapeutics. Cancer rates are expected to rise by 77% by 2050 compared to 2022, highlighting an urgent need for more precise, effective treatment strategies. Traditional treatments like chemotherapy and radiation are often associated with systemic toxicity and limited efficacy. In contrast, NGBT harnesses advanced genomic profiling to tailor therapies to an individual's unique genetic profile, targeting cancer at its molecular root. These therapies are designed to overcome resistance mechanisms and minimize damage to healthy tissues, enhancing therapeutic precision and patient quality of life. As the need for more adaptable and less invasive therapies intensifies, NGBTs are positioned as a vital component in the evolving landscape of oncology treatment.

Key Market Trends

Increasing Aging Population

The global demographic shift toward an older population is a major trend fueling demand for NGBTs. By 2050, the population aged 65 and above is expected to grow to 16%, further increasing to 24% by 2100. With age comes a heightened prevalence of chronic and degenerative diseases such as cancer, cardiovascular disorders, and neurodegenerative conditions. NGBTs provide targeted, innovative therapies tailored to the complex health needs of aging individuals. These biotherapeutics offer a high level of personalization, which is especially critical for elderly patients managing multiple comorbidities. Their potential to reduce hospitalizations and long-term care needs also makes them attractive for healthcare systems aiming to improve outcomes while controlling costs. As aging continues to drive global healthcare demand, NGBTs stand out as a promising solution for personalized, effective disease management in elderly populations.

Key Market Players

  • Xencor, Inc.
  • Regenxbio & Neurimmune AG
  • Takeda Pharmaceutical Company Limited
  • Pfizer, Inc.
  • AstraZeneca Plc.
  • F. Hoffmann-La Roche Ltd.
  • Kyowa Kirin Co., Ltd
  • Seattle Genetics, Inc
  • ImmunoGen, Inc
  • Ono Pharmaceuticals Co, Ltd

Report Scope:

In this report, the Global Next Generation Biotherapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Next Generation Biotherapeutics Market, By Therapeutic Area:

  • Oncology
  • Autoimmune/ Inflammatory Diseases

Next Generation Biotherapeutics Market, By Technology:

  • Antibody-Drug Conjugates
  • Bispecific Antibodies
  • Antibody Fragments
  • Antibody-like Proteins
  • Others

Next Generation Biotherapeutics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Next Generation Biotherapeutics Market.

Available Customizations:

Global Next Generation Biotherapeutics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Next Generation Biotherapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapeutic Area (Oncology, Autoimmune/ Inflammatory Diseases)
    • 5.2.2. By Technology (Antibody-Drug Conjugates, Bispecific Antibodies, Antibody Fragments, Antibody-like Proteins, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Next Generation Biotherapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapeutic Area
    • 6.2.2. By Technology
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Next Generation Biotherapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Therapeutic Area
        • 6.3.1.2.2. By Technology
    • 6.3.2. Canada Next Generation Biotherapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Therapeutic Area
        • 6.3.2.2.2. By Technology
    • 6.3.3. Mexico Next Generation Biotherapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Therapeutic Area
        • 6.3.3.2.2. By Technology

7. Europe Next Generation Biotherapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapeutic Area
    • 7.2.2. By Technology
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Next Generation Biotherapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapeutic Area
        • 7.3.1.2.2. By Technology
    • 7.3.2. United Kingdom Next Generation Biotherapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapeutic Area
        • 7.3.2.2.2. By Technology
    • 7.3.3. Italy Next Generation Biotherapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapeutic Area
        • 7.3.3.2.2. By Technology
    • 7.3.4. France Next Generation Biotherapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Therapeutic Area
        • 7.3.4.2.2. By Technology
    • 7.3.5. Spain Next Generation Biotherapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Therapeutic Area
        • 7.3.5.2.2. By Technology

8. Asia-Pacific Next Generation Biotherapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapeutic Area
    • 8.2.2. By Technology
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Next Generation Biotherapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapeutic Area
        • 8.3.1.2.2. By Technology
    • 8.3.2. India Next Generation Biotherapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapeutic Area
        • 8.3.2.2.2. By Technology
    • 8.3.3. Japan Next Generation Biotherapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapeutic Area
        • 8.3.3.2.2. By Technology
    • 8.3.4. South Korea Next Generation Biotherapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapeutic Area
        • 8.3.4.2.2. By Technology
    • 8.3.5. Australia Next Generation Biotherapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapeutic Area
        • 8.3.5.2.2. By Technology

9. South America Next Generation Biotherapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapeutic Area
    • 9.2.2. By Technology
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Next Generation Biotherapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapeutic Area
        • 9.3.1.2.2. By Technology
    • 9.3.2. Argentina Next Generation Biotherapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapeutic Area
        • 9.3.2.2.2. By Technology
    • 9.3.3. Colombia Next Generation Biotherapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapeutic Area
        • 9.3.3.2.2. By Technology

10. Middle East and Africa Next Generation Biotherapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapeutic Area
    • 10.2.2. By Technology
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Next Generation Biotherapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapeutic Area
        • 10.3.1.2.2. By Technology
    • 10.3.2. Saudi Arabia Next Generation Biotherapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapeutic Area
        • 10.3.2.2.2. By Technology
    • 10.3.3. UAE Next Generation Biotherapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapeutic Area
        • 10.3.3.2.2. By Technology

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Next Generation Biotherapeutics Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Xencor, Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (If Listed)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. Regenxbio & Neurimmune AG
  • 14.3. Takeda Pharmaceutical Company Limited
  • 14.4. Pfizer, Inc.
  • 14.5. AstraZeneca Plc.
  • 14.6. F. Hoffmann-La Roche Ltd.
  • 14.7. Kyowa Kirin Co., Ltd
  • 14.8. Seattle Genetics, Inc
  • 14.9. ImmunoGen, Inc
  • 14.10.Ono Pharmaceuticals Co, Ltd

15. Strategic Recommendations

16. About Us & Disclaimer